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Abstract
Background: Ezrin is a member of the ezrin, radixin, and moesin family that provides a functional link between the plasma
membrane and the cortical actin cytoskeleton. A correlation between ezrin overexpression and aggressive cancer behavior
has been recently reported in various tumor types. However, its roles in the mechanisms underlying progression of tongue
squamous cell carcinoma (SCC) are unclear.
Method: We used human tongue SCC and noncancerous tissue microarrays to immunohistochemically analyze the ezrin
expression level and its relationship with proliferative activity. The human tongue SCC cell line HSC-3 was used to determine
the effects of ezrin RNA interference (RNAi) on cancer cells during MTT; wound healing and invasion assays;
immunofluorescence of the actin cytoskeleton; and western blotting of E-cadherin, N-cadherin, b-catenin, and the active
and total RhoA/Rac1/cdc42.
Results: Ezrin was overexpressed in 46.4% of the tumors examined in human tongue SCC tissue microarrays. Ezrin
expression was correlated with the Ki-67 index. Ezrin depletion by RNAi in the HSC-3 cells significantly reduced cell
proliferation, migration, and invasiveness and disturbed actin reorganization during podia formation. Its effects on RhoA/
Rac1/cdc42 expression were not significant, whereas it enhanced E-cadherin and b-catenin expression and decreased N-
cadherin expression.
Conclusions: Ezrin is often overexpressed in primary tongue SCCs and may have an important role in their growth,
migration, and invasiveness possibly via its relationship with the E-cadherin/b-catenin complex and the cadherin switch.
Thus, ezrin could be a therapeutic target in tongue SCC.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is currently
the seventh most common cancer, with 260,000 new cases
diagnosed each year and approximately 128,000 annual deaths
worldwide [1,2]. The tongue is one of the most common sites of
origin for HNSCC in Japan [3]. Neck lymph node metastasis is
one of the most critical determinants of survival and provides a
good guide for treatment strategies [4–8]. However, the quality of
life and the five-year survival rate are low in advanced tongue
cancers even with current multimodal therapy and surgical
excision accompanied by chemotherapy and radiotherapy. To
improve the outcomes of advanced tongue cancers, we need to
develop new targeted therapies based on an understanding of the
molecular mechanisms underlying the aggressive behavior of
tongue cancers.
Ezrin was initially isolated as a cytoskeletal component of
intestinal microvilli, and it is known to be a substrate of tyrosine
kinase [9]. Ezrin is a member of the ezrin, radixin, and moesin
protein family that links F-actin to cell membrane proteins after
phosphorylation [10–13]. This linker function suggests that ezrin is
essential for many fundamental cellular processes, including
determination of the cell shape, polarity, surface structure, cell
adhesion, motility, cytokinesis, phagocytosis, and integration of
membrane transport through signaling pathways [14–17]. These
functional aspects of ezrin are expected to promote tumor
progression. Indeed, recent studies have revealed that ezrin may
have an important role in tumorigenesis, development, invasion,
and metastasis, probably through regulation of adhesion mole-
cules, participation in cell signal transduction, and signaling to
other cell membrane channels in the tumor [18–22]. Ezrin is an
indispensable factor for tumor cell metastasis in osteosarcomas
[23], breast cancer [24], nasopharyngeal carcinomas [25], and
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prostatic cancer [26]. Ezrin expression has also been linked to
poor survival in several cancers, including carcinomas of the breast
[21,27], endometrium [28], and ovary [29]; cutaneous and uveal
melanomas [30]; and soft tissue sarcomas [31,32]. However, its
roles in oral cancer are unclear. This study aimed to clarify the
roles of ezrin in tongue SCC progression with ezrin RNA
interference (RNAi) in a cell line derived from tongue SCC. We
used primary tongue SCCs to determine the frequency of ezrin
overexpression and the correlations of ezrin expression with the
Ki-67 index and the apoptotic index, which reflect contributions of
cell proliferation and cell loss, respectively, to tumor growth and
aggressiveness. Our results suggest that ezrin may be suitable for
targeted gene therapy in tongue SCCs.
Materials and Methods
Immunohistochemical staining of ezrin and histological
examination
The normal and tumor tongue tissue microarrays of humans
used in this study were obtained from US Biomax Company (MD,
USA). Of the 79 samples, 10 were normal tongue tissues and 69
were tongue SCC tissues. US Biomax Company obtained the
tissue resources from tissue banks who guaranteed that all human
tissue collections were performed at certified hospitals according to
the highest ethical standards. All human tissues were also collected
according to protocols that complied with the Health Insurance
Portability and Accountability Act (HIPPA). They certified that all
tissue banks who provided human tissue resources met the
following requirements of the Human Material Transfer Agree-
ment: the donor’s identity was anonymized and all tissues and data
were labeled using an ID-code to protect the identity of the tissue
donors. Informed consent was kept at tissue banks and not
provided to US Biomax Company, thereby protecting the donor’s
privacy.
Immunohistochemical staining of the human tongue SCC tissue
microarrays was performed using an anti-ezrin rabbit antibody
(#3145; Cell Signaling, MA, USA) and a monoclonal mouse anti-
Ki-67 antibody (clone: MIB-1; Dako, Glostrup, Denmark).
Staining was performed using a Discovery XT Automated IHC
Stainer with a Ventana DABMap Detection Kit (No. 760–124;
Ventana Medical System, AZ, USA). Each step of the Ventana
DABMap Detection Kit procedure was optimized on the
Discovery XT instrument, and the conditions were preset. Antigen
retrieval from the tissue sections was performed using heat.
The staining intensity of human tongue SCC tissue was graded
as follows: 0, negative; 1+, weak; 2+, moderate; and 3+, intense.
This grading used the following criteria: 1+ indicated an intensity
similar to that found in the normal tongue tissue; 3+ indicated
intense staining of the membrane and cytoplasm; 2+ indicated an
intensity between 1+ and 3+. We dichotomized the categories
during statistical analysis. Thus, a weak–moderate staining
intensity indicated low ezrin expression, whereas an intense
staining intensity indicated high ezrin expression.
Ki-67 is usually expressed in the cell nucleus. The Ki-67 index
(i.e., the number of Ki-67-positive tumor cells divided by the total
number of tumor cell6 100%) was determined by counting the
number of tumor cells in three randomly selected high-power
fields (6400).
The apoptotic index was measured using an In situ Apoptosis
Detection Kit (Takara Bio, Otsu, Japan). The staining procedures
followed the manufacturer’s instructions. After routine deparaffi-
nization, the tissue was digested with proteinaseK (20 mg/mL in
PBS) for 15 min at room temperature and washed with PBS.
Slides were then incubated in 3% hydrogen peroxide for 5 min
and washed with PBS. TdT enzyme and substrate was pipetted
onto the sections, which were then incubated at 37uC for 90 min.
After washing, anti-FITC HRP conjugate was added to the slides
for 30 min. The slides were washed, stained with diaminobenzine
(Nichirei, Tokyo, Japan), and counterstained with hematoxylin.
The apoptotic index (the number of positive tumor cells divided by
the total number of tumor cells 6 100%) was determined by
counting the number of tumor cells in three randomly selected
high-power fields (6400). The correlations between ezrin expres-
sion, Ki-67, and the apoptotic index were also evaluated in human
tongue SCC tissues.
Cell culture
The tongue SCC cell line HSC-3 was purchased from the JCRB
Cell Bank and maintained in Dulbecco’s modified Eagle’s medium
(DMEM; Nacalai Tesque, Kyoto, Japan) containing 10% fetal
bovine serum (FBS) and 1% antibiotic–antimycotic solution
(Invitrogen, CA, USA) at 37uC in a humidified atmosphere
supplemented with 5% CO2.
Small interfering RNA (siRNA)
Ezrin siRNA (59-GAUUUCCUACCUGGCUGAAGCUGGA-
39) and nonsilencing control (NSC) siRNA were purchased from
Invitrogen. Cells were transfected using Lipofectamine RNAi-
MAX reagent (Invitrogen), according to the manufacturer’s
instructions. The ezrin siRNA-transfected HSC-3 cells (ezrin-
siRNA) and NSC-transfected HSC-3 cells (NSC) were used in all
of the in vitro experiments.
Quantitative reverse transcription-polymerase chain
reaction (qRT-PCR)
In the qRT-PCR, the total RNA was isolated from cell lines
using RNeasy (Qiagen, Tokyo, Japan) and cDNA was synthesized
from 2 mg of the total RNA. cDNA was subjected to PCR
(LightCycler480, Roche, Tokyo, Japan) using primers and SYBR
Premix Ex Taq II (Takara Bio). All PCR primers were purchased
from Takara Bio and their sequences are shown in Table 1. PCR
was performed using the following conditions: denaturing at 95uC
for 30 s, followed by 40 cycles of PCR at 95uC for 5 s, annealing at
60uC for 20 s, and elongation at 72uC for 10 s. The mRNA
expression levels were normalized against the mRNA expression
levels of the internal standard gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH).
Western blotting
Confluent cells were lysed in lysis buffer (50 mM Tris–HCl,
pH 7.4, 150 mM sodium chloride, 0.5 mM EDTA, 0.09 units/
mL aprotinin, 1 mg/mL pepstatin, 10 mM phenylmethylsulfonyl
fluoride, and 1 mg/mL leupeptin). Protein lysates (20 mg per lane)
detected in the BCA protein assay were separated using a 4%–
12% SDS-PAGE gradient gel (NuPAGE, Invitrogen) and trans-
ferred onto polyvinylidene difluoride membranes (Invitrogen).
Membranes were blocked with 4% nonfat dried milk in TBS-T
Table 1. Primer Sequences used for qRT-PCR.
Ezrin Forward 59- ACCATGGATGCAGAGCTGGAG -39
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(20 mM Tris–HCl, pH 7.5, 8 g/L sodium chloride, and 0.1%
Tween 20) before incubating with primary antibodies.
Anti-ezrin rabbit antibody (#3145) was purchased from Cell
Signaling Technology. Anti-b-actin mouse monoclonal antibody
(sc-47778) and anti-N-cadherin mouse antibody (sc-7939) were
purchased from Santa Cruz Biotechnology (CA, USA). Anti-E-
cadherin mouse antibody (clone 36) and anti-b-catenin mouse
antibody (clone 14) were purchased from Becton Dickinson and
Company (BD; NJ, USA). Goat peroxidase-conjugated anti-rabbit
IgG (#L3012; Signalway Antibody, TX, USA) and goat
peroxidase-conjugated anti-mouse IgG (#AP124P; Millipore,
MA, USA) were used as secondary antibodies. b-actin was used
as the internal positive control. Proteins were visualized using
HRP substrate (Millipore) and scanned with an enhanced
chemiluminescence system (Las 4000; Fuji Film, Tokyo, Japan).
The band intensities were normalized to b-actin.
Cell cycle and apoptosis assay
Cells (16105) were seeded into 75-cm2 flasks and transfected
with ezrin or negative control siRNA. Cells were harvested three
days after transfection and prepared for flow cytometric analysis.
Cells were fixed for 30 min in 70% ethanol and stained with
propidium iodide. Measurements of the DNA cellular content
were performed using a FACSCalibur (BD).
Cell growth assay
An MTT assay was used to evaluate cell growth. Cells were
seeded in 12-well plates (16104 cells/well), and the MTT solution
(0.25 mg/mL) was added to the medium after incubation for 24,
48, 72, or 96 h. Formazan crystals were dissolved in DMSO, and
absorption was measured at 570 nm using an Infinite 200
microplate reader (TECAN, Kawasaki, Japan).
Cell migration assay
Migration was evaluated using a wound healing assay. Cells
were grown in 12-well plates to a near-confluent level in DMEM
containing 10% FBS. Crossed streaks were made on the
monolayer culture using 200-mL pipette tips. The cells were
washed immediately with DMEM containing 10% FBS to remove
the detached cells. Cells were incubated in a medium containing
mitomycin (3 mg/mL; Nacalai Tesque) for 1 h to inhibit
proliferation. Thus, the observed increase in cell number was
not attributable to increased cellular proliferation. Cell migration
was monitored for 0, 12, 24, and 48 h, and images were captured
at each time point using a digital camera (Nikon, Tokyo, Japan)
attached to an inverted phase contrast microscope (Nikon).
Invasion assay
The invasion assays used 24-well BD BioCoat Matrigel invasion
chambers with 8-mm pore inserts (BD). Cells (56104) suspended in
serum-free DMEM were seeded in the upper inserts, while
DMEM containing 10% FBS was added to the lower chambers as
a chemoattractant. The cells were removed from the upper surface
of the filter by scraping with a cotton swab after 22 h in culture.
Cells that infiltrated through the filter were fixed and stained with
hematoxylin–eosin (H/E). The mean values of the results obtained
with the three chambers were used in the analysis.
Immunofluorescence
Cells grown in eight-well culture slides were fixed with 3.7%
formaldehyde in PBS for 30 min, permeabilized with 0.25%
Triton X-100 (Merck CalBiochem, Darmstadt, Germany), and
blocked with 1% FBS in PBS. Actin was stained using rhodamine–
phalloidin (Invitrogen). Immunofluorescence images were visual-
ized using an Olympus BX-61 fluorescent microscope (Olympus,
Figure 1. Immunohistochemical staining of ezrin in human
tongue SCCs and noncancerous tissues. (A) Ezrin expression was
low in noncancerous tissues (magnification 406 and 2006). (B) Ezrin
was highly expressed in tongue squamous cell carcinomas (magnifica-
tion 406 and 2006). Ezrin immunoreactivity was apparent in the
membrane of normal tongue epithelium, whereas positive staining for
ezrin was primarily in the cytoplasm or in the membrane and cytoplasm
of tongue squamous cell carcinoma cells.
doi:10.1371/journal.pone.0054881.g001
Table 2. Association between ezrin expression and clinico-
pathologic variables in 79 tongue tissue.
Ezrin expression
low high




n= 69 37 (56.3%) 32 (46.4%)
TNM staging
stage I n = 24 12 (50.0%) 12 (50.0%)
stage II n = 29 18 (62.1%) 11 (37.9%)
stage III n = 12 5 (41.7%) 7 (58.3%)
stage IV n = 4 2 (50.0%) 2 (50.0%)
Lymph node metastasis
lymph node metastasis2 n= 61 34 (55.7%) 27 (44.3%)
lymph node metastasis+ n= 8 3 (37.5%) 5 (62.5%)
Pathology diagnosis
Grade1(well-differentiated) n = 50 26 (52.0%) 24 (48.0%)
Grade2(moderately-
differentiated)
n = 11 6 (54.5%) 5 (45.5%)
Grade3(poorly-differentiated) n = 8 5 (62.5%) 3 (37.5%)
Grade4(undifferentiated) n = 0 – –
doi:10.1371/journal.pone.0054881.t002
Ezrin Overexpression in Tongue SCC
PLOS ONE | www.plosone.org 3 January 2013 | Volume 8 | Issue 1 | e54881
Tokyo, Japan), and images were captured with a CoolSNAP-HQ
camera (NIPPON ROPER, Tokyo, Japan).
Rho family activity assay
Rho family activation assay was also performed using an RhoA/
Rac1/Cdc42 Activation Combo Kit (Cell Biolabs, San Diego, CA,
USA), according to the manufacturer’s instructions. In brief, cells
were washed, lysed in assay buffer, and centrifuged at 10,0006g
for 1 min to remove cell debris. To determine the total expression
levels of RhoA/Rac1/Cdc42 by western blotting, 20 mL of each
sample was stored at 280uC for separate analysis. A cell lysate
containing 500 mg of total protein was incubated for 1 h at 4uC
with rotation with 40 mL of the agarose beads, which bound
activated RhoA, Rac1, and Cdc42. Agarose beads bound to active
RhoA/Rac1/Cdc42 were washed three times using assay buffer,
resuspended in 40 mL of 26 LDS sample buffer, and boiled at
70uC for 10 min. The active (GTP-bound) and total RhoA/Rac1/
Cdc42 protein levels in each sample were determined by western
blotting.
Statistical analyses
Each experiment was performed in triplicate. All data were
expressed as the mean 6 SD. Statistical analysis was performed
using Excel (Microsoft, WA, USA). Comparisons between groups
were conducted using the Student’s t-test. The correlation of the
ezrin expression levels with tongue SCC and lymph node
metastasis was analyzed using Fisher’s exact test, whereas the
stage and differentiation grades were analyzed using Tukey’s
multiple comparison method. Differences were considered statis-
tically significant at P,0.05.
Results
Ezrin expression in tongue cancer and noncancerous
tissues
Ezrin immunoreactivity was observed in the cell membranes,
while it was weakly positive in the cytoplasm of normal tongue
mucosa (Fig. 1A). In contrast, tongue SCC samples demonstrated
Figure 2. Correlations between ezrin expression and the indices of Ki-67 and apoptosis in human tongue SCC tissues. (A) The Ki-67
index was 33.0619.3% in tissues with low ezrin expression and 48.1615.0% in tissues with high ezrin expression. Significant differences were
observed in correlation between ezrin expression and the Ki-67 index (P= 0.0003). (B) There was no significant correlation between ezrin expression
and apoptotic indices (P= 0.5776).
doi:10.1371/journal.pone.0054881.g002
Figure 3. The expression of ezrin in HSC-3 tongue SCC cells
after siRNA treatment. (A) Ezrin mRNA expression was analyzed
using real-time PCR after RNAi. The inhibition of ezrin mRNA expression
was clearly observed in ezrin siRNA-transfected HSC-3 cells compared
with that in HSC-3 control cells (0.1060.03 vs 1.0660.21; P,0.05). (B)
Ezrin protein expression was detected by western blotting after RNAi.
The expression of ezrin decreased dramatically in ezrin siRNA-
transfected HSC-3 cells.
doi:10.1371/journal.pone.0054881.g003
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membranous and cytoplasmic ezrin staining, and the cytoplasmic
staining was greater in these samples than in the normal tongue
mucosa samples (Fig. 1B). Table 2 presents the results of ezrin
staining. In noncancerous human tongue tissues, all 10 samples
expressed ezrin at low levels. In human tongue SCC tissues,
however, high ezrin expression was detected in 32/69 (46.4%)
tumors, whereas low expression was detected in 37/69 (53.6%)
tumors. High ezrin expression was significantly more common in
human tongue SCC tissues than in noncancerous tissues
(P = 0.0046). High ezrin expression tended to be detected more
frequently in the cases with lymph node metastasis (62.5%) than in
with those without lymph node metastasis (44.3%), but there was
no significant correlation between the ezrin expression levels and
the stage grade, regional lymph node metastasis, and the
differentiation grade (P.0.05).
Correlations between ezrin expression and the indices of
Ki-67 and apoptosis in human tongue SCC tissues
We evaluated the correlations between ezrin expression and the
Ki-67 and apoptotic indices in human tongue SCC tissues. The
Ki-67 index was 33.0619.3% in tissues with low ezrin expression
levels and 48.1615.0% in tissues with high ezrin expression levels
(Fig. 2A). There was a positive correlation between ezrin
expression levels and the Ki-67 index (P = 0.0003). The apoptotic
index was 0.6060.74% in tissues with low ezrin expression levels
and 0.7060.78% in tissues with high ezrin expression levels
(Fig. 2B). There was no significant correlation between the ezrin
expression levels and the apoptotic index (P = 0.5776).
Ezrin gene expression in the human tongue SCC cell line
HSC-3 after RNAi
To examine the effects of ezrin siRNA treatment on the HSC-3
cells, we used qRT-PCR and western blotting to measure the ezrin
mRNA and protein levels, respectively, in the HSC-3 cells that
were transfected with siRNA. As shown in Figure 3A, the ezrin
mRNA expression was clearly inhibited in the ezrin-siRNA cells
than in the NSC cells (0.1060.03 vs 1.0660.21; P,0.05). The
western blot analysis demonstrated that RNAi reduced the ezrin
protein levels (Fig. 3B).
Figure 4. Cell cycle changes after RNAi treatment. The proportion of HSC-3 cells in the S phase decreased from 50.861.6% to 36.660.4% after
RNAi (P= 0.0018). The proportion of cells in the G0/G1 phase also increased from 37.764.9% to 54.160.5% after RNAi (P= 0.0018). Apoptosis was not
detected.
doi:10.1371/journal.pone.0054881.g004
Figure 5. Effects of ezrin downregulation on HSC-3 cell growth.
The growth of ezrin siRNA-transfected HSC-3 cells decreased in a time-
dependent manner. (24 h: P= 0.6727; 48 h: P=0.5314; 72 h: P= 0.0122;
96 h: P=0.0065).
doi:10.1371/journal.pone.0054881.g005
Figure 6. Cell wound healing assay. Cells were wounded by
scratching with a pipette tip, and mitomycin (3 mg/mL) was added to
the medium for 1 h to inhibit the proliferation of cancer cells. Cells were
subsequently incubated with DMEM for 48 h. Cells were photographed
using phase-contrast microscopy. HSC-3 cell migration was reduced by
ezrin siRNA treatment.
doi:10.1371/journal.pone.0054881.g006
Ezrin Overexpression in Tongue SCC
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Effects of ezrin RNAi on cell cycle progression and
apoptosis
We transfected the HSC-3 cells with ezrin siRNA and collected
them after three days for cell cycle analysis. Flow cytometry
showed that the G0/G1 fraction increased from 37.7%64.9% to
54.1%60.5% (P = 0.0046) in the HSC-3 cells after RNAi (Fig. 4).
In contrast, the S and G2/M fractions were decreased in the HSC-
3 cells after RNAi. In particular, the proportions of S phase cells
decreased from 50.8%61.6% to 36.6%60.4% (P = 0.0018),
whereas the proportion of the G2/M cells decreased from
11.5%63.3% to 9.3%60.9% (P = 0.1155). No preG0/G1 cells
or apoptotic bodies were observed in the control and siRNA-
transfected cells. These results suggest that ezrin siRNA may
inhibit cell proliferation by interfering with cell mitosis and cell
cycle progression.
Effects of ezrin RNAi on cell growth
The effects of ezrin protein expression on cell growth were
tested using an MTT assay. The growth rate of the ezrin siRNA-
treated cells decreased in a time-dependent manner (Fig. 5). The
absorbance values of the MTT assay after 72 h were 0.3660.02
and 0.3060.01 for the NSC- and ezrin siRNA-transfected HSC-3
cells, respectively. These data indicate that there was a significant
reduction in cell growth in the ezrin siRNA-transfected cells than
in the control cells.
Effects of ezrin RNAi on cell migration and invasion
Wound healing assays were conducted to evaluate the cell
motility of the NSC- and ezrin siRNA-transfected cells. A wound
was created on a cell monolayer, and wound closure was assessed
at various time points. Ezrin silencing in the HSC-3 cells impaired
their ability to heal a wound compared with that in control cells
that expressed ezrin (Fig. 6). Invasion assays were also performed
using Matrigel-coated Transwell culture chambers, and the
invading cells were counted after 22 h. The ezrin siRNA-
transfected cells exhibited a four-fold lower cell invasion rate than
the NSC-transfected cells that expressed ezrin (564.76111.8 vs
1969.86126.6; P,0.05; Fig. 7).
Effects of ezrin RNAi on actin cytoskeleton reorganization
We analyzed the effects of ezrin downregulation on the
organization of the actin cytoskeleton. Analyses of phalloidin-
stained cells showed that podia formation was clearly inhibited in
the ezrin siRNA-transfected cells (Fig. 8). These findings indicated
that the absence of ezrin caused morphological changes in cancer
cells through actin cytoskeleton remodeling.
Rho family proteins, E-cadherin, N-cadherin, and b-
catenin expression in the ezrin-depleted cells
There were no differences in the total protein levels of RhoA,
Rac1, and Cdc42 (Fig. 9), and the levels of their active forms were
too low to be detected in the NSC- and ezrin siRNA-transfected
cells.
We tested whether the expression levels of E-cadherin, N-
cadherin, and b-catenin were affected by ezrin depletion in the
HSC-3 cells by quantifying their expression using western blotting.
As shown in Figure 9, E-cadherin and b-catenin expressions were
increased, whereas N-cadherin expression was decreased in the
ezrin siRNA-transfected cells than in the NSC-transfected cells.
These results indicate that suppression of ezrin protein expression
induced the upregulation of E-cadherin and b-catenin but the
downregulation of N-cadherin in the HSC-3 cells.
Discussion
Tissue microarray analyses showed that high ezrin expression
was significantly more common in the human tongue SCC tissues
than the noncancerous tissues (P = 0.0046). There was also a
positive correlation between ezrin expression and the Ki-67 index
in this study. The Ki-67 antigen is expressed by proliferating cells
during the G1, S, G2, and M phases, but not during the G0 phase
(resting cells) [33]. Ki-67 is used as a marker of tumor proliferation
and aggressiveness, and it can have a major effect on the prognosis
of patients with HNSCC [34]. High ezrin expression tended to be
detected more frequently in cases with lymph node metastasis
(62.5%) than in those without lymph node metastasis (44.3%). Our
in vitro experiments using the human tongue SCC cell line HSC-3
with and without RNAi treatment also detected an association
between ezrin overexpression and more aggressive behavior,
whereas there were no significant correlations between the ezrin
expression patterns and TNM staging in human tongue SCC
tissues. Nicolas et al. also reported no significant difference in ezrin
expression in advanced and lower TNM stage tumors, whereas
high levels of ezrin and moesin expression were associated with
poor cancer survival [35,36]. These findings suggest that ezrin
Figure 7. Invasion assay. (A) Matrigel-coated Transwell chambers
were used to analyze cell invasion. Cells that infiltrated through the
filter were fixed and stained, and representative fields were photo-
graphed. (B) The cells were quantified by counting under a light
microscope. Compared with the HSC-3 control cells, the ezrin siRNA-
transfected HSC-3 cells exhibited significantly decreased invasiveness
(1969.86126.6 vs 564.76111.8; P,0.05).
doi:10.1371/journal.pone.0054881.g007
Figure 8. Immunofluorescence. NSC- and ezrin siRNA-transfected
HSC-3 cells were labeled with an antibody against actin. Ezrin depletion
of HSC-3 cells led to reduced ezrin protein levels. This downregulation
was associated with the loss of protrusions (arrows).
doi:10.1371/journal.pone.0054881.g008
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overexpression can be used as a prognostic marker independently
of TNM staging.
The in vitro roles of ezrin in cellular behavior have not been
evaluated in tongue SCCs. Our RNAi experiments detected strong
suppression of cell growth, motility, and invasiveness in the HSC-3
tongue SCC cells. The cell cycle analysis revealed that ezrin
depletion increased the G0/G1 fraction but decreased the G2-M
fraction by interfering with cell mitosis and cell cycle progression.
These results agree with those reported by Zhang et al. in
hepatocellular carcinoma [37]. They also indicated that ezrin
could enhance the growth of cancer cells by supporting cell
division and cell cycle progression from G0/G1 to the S and G2/
M phases. This agreed with the results of the tissue microarray Ki-
67 index. We also observed that ezrin depletion inhibited cell
growth in an MTT assay.
Cell migration and invasion are essential processes in the
metastasis of cancer cells. Migratory cancer cells undergo a series
of morphological changes via reorganization of adhesion mole-
cules and actin fibers [38]. It is now widely accepted that the
process of cancer cell migration involves four main steps—
formation and extension of filopodia and lamellipodia at the
leading edge, establishment of new adhesion sites at the front,
contraction of the cell body, and detachment of adhesions at the
rear [39]. We observed that ezrin depletion decreased cancer cell
motility and invasiveness and inhibited podia formation. These
results indicate that ezrin inhibition disturbed remodeling of the
actin cytoskeleton, which reduced the motility and invasiveness of
the HSC-3 cells. These findings agree with previous reports, which
showed that changes in the cytoskeleton may be a key factor in the
regulation of neoplastic progression and tumor growth [24,40–43].
A previous study also detected a dramatic reduction in the number
of pancreatic cancer cells with podosomal rosettes after ezrin
RNAi treatment and reported that formation of podosomes and
their rosettes was driven by an ezrin–cortactin interaction, which
has a role in pancreatic cancer invasion [44]. Another report
revealed that pseudopod formation was clearly decreased by ezrin
RNAi treatment in four hepatocellular carcinoma cell lines [37].
Our results suggest that ezrin plays an important role in the
invasive growth of tongue SCCs. We also examined actin, Rho
family proteins, E-cadherin, N-cadherin, and b-catenin to
investigate the molecular mechanisms underlying these observa-
tions. We found that ezrin suppression induced the enhanced
expression of E-cadherin and b-catenin in the HSC-3 cells. It is
known that E-cadherin plays a central role in epithelial cell–cell
adhesion and the maintenance of epithelial cell colony integrity
[45]. It is well documented that the loss or inhibition of E-cadherin
function, or its associated catenins, leads to reduced intercellular
adhesion and an increased invasive potential [46]. Moreover,
several studies of epithelial malignancies, including oral SCCs,
have suggested that the E-cadherin/b-catenin complex regulates
cancer invasion and metastasis [47,48]. Cadherin adhesion
complexes interact with the actin cytoskeleton in a complex
manner, which is poorly understood. The current view is that E-
cadherin is linked to the actin cytoskeleton through its interaction
with b-catenin, which in turn binds the actin-binding protein a-
catenin [49]. Recent evidence suggests that ezrin is important for
localization of E-cadherin to the plasma membrane [24]. Thus, we
hypothesized that the E-cadherin and b-catenin downregulation
linked to ezrin overexpression may have been associated with actin
remodeling and the formation of podia extensions.
It is widely known that actin reorganization is regulated by the
Rho family small GTPases such as Rho, Rac, and Cdc42 [50], i.e.,
Rho regulates stress fiber and focal adhesion assembly, Rac
regulates the formation of lamellipodia protrusions and membrane
ruffles, and Cdc42 triggers filopodial extensions at the cell
periphery [51]. We examined the expression and activity of
RhoA, Rac1, and Cdc42 in the ezrin siRNA- and NSC-
transfected HSC-3 cells. However, there were no differences in
Figure 9. Western blot analyses of E-cadherin, N-cadherin, b-catenin, and Rho family proteins in HSC-3 cells. The expression of E-
cadherin and b-catenin was increased and the expression of N-cadherin was decreased in ezrin siRNA-transfected HSC-3 cells compared with that in
the NSC-transfected cells. There was no significant difference in the total protein levels of RhoA, Rac1 and Cdc42.
doi:10.1371/journal.pone.0054881.g009
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the total protein levels of RhoA, Rac1, and Cdc42, and the level of
their active forms were too low to detect, irrespective of ezrin-
siRNA transfection. It is unclear whether these findings reflect the
low significance of Rho family proteins in the motility of the HSC-
3 cells.
In our RNAi experiments, ezrin suppression induced E-
cadherin upregulation and N-cadherin downregulation. This
indicates that ezrin may be correlated with cadherin switching
and epithelial-to-mesenchymal transitions (EMT). Numerous
studies have suggested that EMT is a potent mechanism that
enhances the detachment of cancer cells from a primary tumor
and their migration into the tumor stroma, vessels, and metastatic
sites [52–54]. Cadherin switching is also essential for increased
motility [54]. Previous reports indicate that ezrin is associated with
several signaling cascades. In colon cancer, ezrin interacts with
L1CAM and regulates NF-kB signaling [55]. Ezrin silencing
downregulates the MAPK and TGF-b pathways in esophageal
SCC [56]. Ezrin also participates in the activation of MAPK and
PI3K in breast and prostate cancer [57]. There is a possibility that
ezrin affects cadherin switching and EMT induction through
signaling modifications. Further studies are necessary to explore
the correlation between ezrin expression and EMT.
Ezrin is known to be essential for many fundamental cellular
processes [14–17] and is also related to the malignant behavior of
various malignant tumors [18–32]. The present study suggests that
ezrin is also related to the malignant behavior of tongue SCC cells
through various aspects of the functional roles of ezrin, including
its upregulation of cell growth by accelerating cell cycle
progression and its upregulation of cell motility and invasiveness
through remodeling of actin fibers and podia formation. Ezrin was
often overexpressed in primary tongue SCCs; thus, it may also
play an important in vivo role in the malignant behavior of tongue
SCCs. This suggests that ezrin may be a potential target for the
treatment of human tongue cancers.
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